Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Published:2020-01 Issue:1 Volume:21 Page:33-43
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Prat Aleix,Saura Cristina,Pascual Tomás,Hernando Cristina,Muñoz Montserrat,Paré Laia,González Farré Blanca,Fernández Pedro L,Galván Patricia,Chic Núria,González Farré Xavier,Oliveira Mafalda,Gil-Gil Miguel,Arumi Miriam,Ferrer Neus,Montaño Alvaro,Izarzugaza Yann,Llombart-Cussac Antonio,Bratos Raquel,González Santiago Santiago,Martínez Eduardo,Hoyos Sergio,Rojas Beatriz,Virizuela Juan Antonio,Ortega Vanesa,López Rafael,Céliz Pamela,Ciruelos Eva,Villagrasa Patricia,Gavilá Joaquín

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Trends and predictions to 2020 in breast cancer mortality in Europe;Carioli;Breast,2017

2. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 120 000 women in 123 randomised trials;Lancet,2012

3. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer;Cejalvo;Cancer Treat Rev,2018

4. Practical implications of gene-expression-based assays for breast oncologists;Prat;Nat Rev Clinl Oncol,2012

5. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer;Sparano;N Engl J Med,2018

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI);Cancers;2024-09-10

2. Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study;2024-09-01

3. Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis;Frontiers in Immunology;2024-08-23

4. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer;Current Treatment Options in Oncology;2024-08-15

5. The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer;Future Oncology;2024-07-29